Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 May;86(5):e138-e141.
doi: 10.1016/j.jinf.2023.01.030. Epub 2023 Jan 22.

Acceptance, safety and immunogenicity of a booster dose of inactivated SARS-CoV-2 vaccine in adults with tuberculosis

Haoting Zhan  1 , Li Yang  2 , Yongmei Liu  1 , Haolong Li  1 , Xiaomeng Li  3 , Haibin Wang  4 , Jinfeng Cao  4 , Shuhui Kang  4 , Xinru Guo  2 , Erhei Dai  5 , Yongzhe Li  6
Affiliations

Acceptance, safety and immunogenicity of a booster dose of inactivated SARS-CoV-2 vaccine in adults with tuberculosis

Haoting Zhan et al. J Infect. 2023 May.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Declaration of Competing Interest The authors have no conflict of interest declared and declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Fig 1
Fig. 1
Levels, positivity and neutralizing effect on wild type (WT) and Omicron subvariant BA.4/5 of SARS-CoV-2 specific antibodies among adults with TB. (A-C) Levels (OD value) of total antibodies against SARS-CoV-2, inhibition rates (%) of neutralizing antibodies (NAbs) against WT and Omicron subvariant BA.4/5 evaluated by SARS-CoV-2 surrogate virus neutralization test (sVNT) among adults with TB received third (booster) dose of inactivated COVID-19 vaccine, third dose (complete regime) of recombinant protein vaccine, second dose of inactivated vaccine and those unvaccinated TB patients. HCs were age-, gender- and vaccination time-matched with TB patients who have inoculated second and third (booster) dose of inactivated vaccine. Antibody positivity was shown each panel below the figures where positive rate was presented as dark red for adults with TB and as dark blue for HCs. Optical density (OD) values above 0.19 were regarded as positive for total antibodies against SARS-CoV-2. Inhibition rate above 30% were regarded as positive. (D) Inhibition ability of NAbs against BA.4/5 (purple bar) and against WT (dark blue bar) among adults with TB and HCs. Seropositivity of NAbs against BA.4/5 remained below positive threshold (30%) at all sampling time after vaccination.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Moussaoui ME, Desmecht S, Tashkeev A, Lambert N, Maes N, Braghini J, et al. Reduced T-cell response following a third dose of SARS-CoV-2 vaccine in infection-naïve people living with HIV. J Infect. 2022;85(6):702–769. - PMC - PubMed
    1. WHO. Global tuberculosis report 2022. https://www.who.int/teams/global-tuberculosis-programme/tb-reports/globa....
    1. Furin J, Cox H, Pai M. Tuberculosis. Lancet. 2019;393(10181):1642–1656. - PubMed
    1. Deepak P, Kim W, Paley MA, Yang M, Carvidi AB, Demissie EG, et al. Effect of Immunosuppression on the Immunogenicity of mRNA vaccines to SARS-CoV-2 : a prospective cohort study. Ann Intern Med. 2021;174(11):1572–1585. - PMC - PubMed
    1. Parker EPK, Desai S, Marti M, Nohynek H, Kaslow DC, Kochhar S, et al. Response to additional COVID-19 vaccine doses in people who are immunocompromised: a rapid review. Lancet Glob Health. 2022;10(3):e326–e3e8. - PMC - PubMed

Publication types

Supplementary concepts